ISRCTN02847428
Completed
未知
To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients: an interventional pilot multicentre study
Baxter (Italy)0 sites11 target enrollmentSeptember 13, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Haemophilia
- Sponsor
- Baxter (Italy)
- Enrollment
- 11
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adult subjects with haemophilia A of any severity with or not suppressant
- •2\. Age more than or equal to 18 years
- •3\. Subjects who have been previously diagnosed with a chronic articular inflammatory process or hematoma
- •4\. Subjects who have signed an informed written consent
Exclusion Criteria
- •Subjects with under way bleeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Clinical study on Abhraloha in iron deficiency AnemiaCTRI/2019/01/017303Shree Dhootapapeshwar Limited57
Completed
Phase 1
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment PeriodACTRN12622000680763Hope Medicine (Nanjing) Co., Ltd16
Active, not recruiting
Phase 1
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
Active, not recruiting
Phase 1
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
Completed
Phase 1
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10